Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Clofarabine.

Ching-Hon Pui¹, Sima Jeha

¹Leukemia/Lymphoma Division, St Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA. ching-hon.pui@stjude.org

Nature Reviews. Drug Discovery

|June 21, 2005

Summary

This summary is machine-generated.

Clofarabine (Clolar) is a new purine nucleoside antimetabolite approved for treating paediatric acute lymphoblastic leukaemia. This marks a significant advancement, being the first new drug for this condition in over a decade and approved for children first.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022

Same author

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome.

Blood advances·2022

Same author

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Blood·2022

Same author

Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.

Nature genetics·2022

Same author

Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.

JAMA oncology·2022

Same author

Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.

Children (Basel, Switzerland)·2021

Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026

Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026

Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026

Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026

Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026

Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026

See all related articles

Area of Science:

Oncology
Pharmacology
Paediatric Medicine

Background:

Clofarabine (Clolar) is a purine nucleoside antimetabolite.
Acute lymphoblastic leukaemia (ALL) is a significant challenge in paediatric oncology.
Limited novel therapeutic options have been available for relapsed or refractory paediatric ALL.

Purpose of the Study:

To present the accelerated approval of Clofarabine for paediatric ALL.
To highlight Clofarabine's unique regulatory pathway for paediatric use.

Main Methods:

Review of regulatory submission and approval data.
Analysis of Clofarabine's classification as a purine nucleoside antimetabolite.

Main Results:

Clofarabine received accelerated approval from the US FDA in December 2004.

Related Experiment Videos

It is indicated for paediatric patients with relapsed or refractory acute lymphoblastic leukaemia.

This approval represents the first new drug for paediatric leukaemia in over 10 years.

Conclusions:

Clofarabine offers a new treatment option for a challenging paediatric cancer.
The drug's approval prioritizes paediatric use, addressing an unmet need.
This milestone signifies progress in paediatric oncology drug development.